Human genetics studies have identified Bin1 as second only to ApoE as a risk factor for late-onset Alzheimer’s disease (LOAD). Neurology studies indicate that Bin1 binds and influences the turnover of tau as a likely mechanism in promoting LOAD risk. Lankenau Institute for Medical Research scientists developed a cell-penetrating Bin1 antibody that appears to promote […]
Therapeutics & Prevention
Lankenau Institute for Medical Research scientists have developed a radically new approach to eradicate topical infections by weakening the local ecology of the infection that supports it. Specifically, they have developed topical over-the-counter (OTC) formulations of safe and effective agents that are capable of clearing recalcitrant topical infections such as onychomycosis, Staph, or plantar wart. […]
Taking a radically new approach to eradicate topical infections, LIMR researchers have developed a set of topical over-the-counter (OTC) formulations of safe and effective agents. Their new approach is based on the concept of treating the infection ecology, which includes not only the microbial agent but also (1) the local supportive microbiome for the microbe, […]
Rheumatoid arthritis (RA) is a chronic autoimmune disease that occurs when the body’s immune system attacks joints, creating debilitating inflammation and pain. Left unchecked this inflammatory condition can permanently damage joint structures, and in some cases, damage the cardiovascular and respiratory systems. This systemic disease affects more than 1.5 million Americans and about 1% of […]
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness and visual impairment in the world. It strikes mostly people age 60 or older. AMD causes an irreversible destruction of the macula, the part of the retina responsible for vision, thereby leading to vision loss. LIMR technology specifically address the wet form of AMD […]